Catastrophic Success
John Mauldin
December 20, 2011
这篇文章是不是在中国发售。为了您的方便,这里是英语语言版本。
New
readers to my musings often find it interesting, when they meet me in person,
to find me quite an optimistic person, given the nature of my current
predictions about the economy. And regarding the short term, defined as less
than five years, my writing is admittedly less than sanguine. We do have some
problems that are not easily dealt with. And even longer-term, those of a
bearish natural disposition can find reasons a-plenty to tone it down.
But
five years (at least at my age) is not all that long. One way or another we
will get through the current mess. My studies on the nature of progress in a
number of fields give me a rather optimistic longer-term slant on life, and
most especially in biotechnology. Long-time readers know of my interest in the
potential for biotechnology to be completely transformational and disruptive
(in a positive way) to society. It is one of the few places I am "long" and
willing to get even more long.
Today's
Outside the Box is from a source that is no stranger to my regular readers. Pat
Cox called last week and told me about an amazing announcement that was made
public last Friday, so we are almost "breaking news" here this week. BioTime
(BTX) has announced the ability to detect most cancers with a simple blood test
that detects markers. This holds the prospect that within a very few years we
will all routinely get a blood test for cancer as part of our regular blood
work, allowing for very early detection. And as Pat notes, cancer becomes far
more treatable if detected early.
As
Pat and I talked, I asked him to give us an update on the BioTime story but
also on the state of some of the really promising cancer cures. And let me
note, these are but a few. There are literally dozens, if not hundreds, of real
potential cures. We do live in remarkable times. Comments in the text below in
brackets [ ] are mine.
Pat
is one of my favorite sources for new, transformational technology. We talk
regularly and compare notes. Pat (like me) likes to look over the horizon and
think about what is coming. The companies he writes about are typically
early-stage research and development plays, in a variety of fields (not just
biotech – last month he was writing about robotics!).
You can subscribe to his
letter by going to http://www.PatCoxLetter.
Warning: his publisher likes rather aggressive marketing, but I just like his
letter and research.
Note: I have invested
(for quite some time now) in some of the companies he mentions below or have
associations with them that I note in the copy. And some I have no knowledge
of.) I have not done any transactions in the last few months and will not do
anything for at least two weeks. And do NOT chase these stocks. They are
typically very small-cap with smaller volumes, and are research and development
companies with no guarantees of success. Do your homework, and if you buy then
do it for the long term.
I do comment below on one
private firm that some of you who sit on foundations and charities that focus
on cancer and heath care might want to look into.
Now
let's take a look at what Pat and I sincerely hope is the future.
Your planning to live a lot longer than you think
analyst,
John Mauldin, Editor
Outside the Box
JohnMauldin@2000wave.com
Catastrophic Success
By Pat Cox, Editor
Breakthrough
Technology Alert
When the second stimulus bill passed in February,
2009, I explained to my readers that the "crowding out effect" would guarantee
its failure. I took no pleasure in predicting accurately that increased
government borrowing would crowd out private investment in innovation, from
which flows economic and employment growth.
I bring this up simply because I have
extraordinarily good news regarding cancer therapeutics,...
Comments
Pedro Gonzalez
Dec. 21, 2011, 7:14 a.m.
Mr. Mauldin you wrote on 12/20/201 Outside the Box E-Letter, Catastrophic Success the following stement “... my interest in the potential for biotechnology to be completely transformational and disruptive (in a positive way) to society.” What society? The top 1% earners of developed countries societies?
Gerald Ferguson
Dec. 20, 2011, 7:17 p.m.
A valuable article, but I don’t understand the reference to “intellectuals’ as not knowing about failings in our economy. Authors, composers, scientists, artists, musicians, are not who I think of with knowledge of Wall Street or the housing market. Instead, economists and politicians are more to the point, and they do not spring to mind as “intellectuals”.
Barry Mannefeld
Dec. 20, 2011, 7:04 p.m.
I don’t see this as so catastrophic John. In fact, if it is as you write it, the productive life of Americans could be extended enough to solve the demographic problem. Also, the high costs of dying could be put off for several years, shifting the annuity payout backwards, allowing for more accumulation. Third, we would have a systematic liquidation of savings that would allow for the transfer to the younger working generation. I would have to examine this last thought. Most productive people in the US don’t quit working until they have to, from what I have seen.
Paul Accampo
Dec. 20, 2011, 7 p.m.
We have more cancer today because we are living long enough for our teleomeres to run out, enabling it to develop. Curing all cancers with a drug will allow more of us to live longer, but bring on the next cause of death, increasing medical bills and bankrupting Social Security. At some point we have to acknowledge that we are not immortal.
Keating Willcox
Dec. 20, 2011, 6:30 p.m.
The entitlement problem will solve itself. Medical services will start to follow a Amazon.com like pattern of customer choice and intense competition. And, all of us will be working far longer than 65. Plus, many older folks will find less expensive forms of long term care, and spend their retirement outside of nursing homes.
I think our real problem is the large number of working age people who are unable to perform at good technical jobs of this economy. How does a 9th grade drop out ever make enough to provide a decent living and pay taxes as well.
garry madaline
Dec. 20, 2011, 3:16 p.m.
It’s amazing to me that you can get this much information together in such a short period of time. You have an incredible knack for getting to the heart of most matters and then give another point of view from someone that doesn’t subscribe to your wisdom. I recently passed on your catastrophic success article to my daughter (a doctor) and my 93 year old father’s oncologist. This information is incredible but most important is the opportunity that is being given to us to straighten out a very sick economy that has been made sick by people with personal (get re-elected, make me rich) agendas. I would love to hear your wisdom on how to change the powers that be to those who want to move forward for the good of mankind. Don’t take this as a liberal attitude as I am quite conservative but more of, at the risk of sounding corny Star Trek. Thanks for the hard work and keep it up. I have a newsletter I send to people with 401(k)s and I would like to send them information to link up to you if that’s possible.
Larry Brown
Dec. 20, 2011, 3:13 p.m.
There has been a “general purpose” cancer test available for at least 20 years. It is 95% accurate wth one test and nearly 100% accurate with two tests. It is 0% accurate it specificing where the cancer is (which is why doctors do use it). It costs $200 and is called the AMAS test.
Michael Gorback
Dec. 20, 2011, 3:09 p.m.
BioTime is a “story” stock and the story keeps changing. See http://www.johnmauldin.com/outsidethebox/want-a-new-cardiovascular-system/. The stock was about $8 then. In the past week or so it has moved from $3.50 to $5.50.
Now they are cancer-detection company.
Before going any further let me state that I am a physician with over 30 years in practice. I have lived through all sorts of medical fads, including the fads for easy tests for cancer.
This is not a simple straightforward process. PSA for prostate cancer screening has had its ups and downs - lately mostly downs. The thinking is gradually coming around to abandoning PSA as a screening tool because of the high false-positive rate.
My family had its own experience with the ovarian cancer marker CA-125 when someone developed postmenopausal bleeding. Uterine biopsies, hysteroscopy and ultrasound were negative but a subsequent CA-125 was 3X normal. The family was in total panic and an appointment with an oncologic GYN surgeon was arranged.
I was suspicious about this because CA-125 can go up for reasons other than cancer. I reasoned that with all the jiggering around with multiple biopsies, a trial of hormone therapy, etc, the CA-125 was artifactually high. I asked for a repeat that came back normal.
So these tests can INCREASE the amount of unnecessary medical care one receives, and not all of that medical care is risk-free (very little medical care is risk-free; perhaps one could argue that none of it is). If I hadn’t pressed for a repeat CA-125 we were probably looking at an exploratory surgery and hysterectomy/ovariectomy.
BioTime’s markers might be truly game-changing technology but it has yet to even undergo clinical trials. This is still just a “story” stock. After reading the fluff about BioTime I didn’t bother reading the rest of the so-called analysis.
Dan Ross
Dec. 20, 2011, 1:02 p.m.
Fascinating technology. The concluding observation regarding pushing out retirement age is only half of the issue. The obvious conclusion is that people must be intellectually capable of continuing to be productive, employed citizens.
Today we face the paradox of both age discrimination in the work force AND inter-generational competition for jobs. Today, employers look at the difference in experience and the difference in price. It ends up being a simple decision in many cases for a broad class of jobs.
Although it would be nice to posit a world where all people have the entrepreneurial attitude and ability to change during a potential century of employment, I don’t see this happening. Maybe it will evolve on its own but I don’t see anything other than anecdotal evidence that it is beginning. You know, all the great stories of people sky-diving at age 90 and beginning new careers at 70. Like it or not, the bell curve governs the human population.
(John, I know you like Asimov. Remember the Settler worlds and their robots!)
At the end of the day, I think this is the biggest challenge, not the technology.